XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
XELOX（卡培他滨加奥沙利铂）加贝伐单抗（抗 VEGF-A 抗体）联合或不联合过继细胞免疫疗法治疗既往未接受治疗的转移性结直肠癌患者：一项多中心、开放标签、随机、对照的 3 期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-024-01788-2
Pan Qiu-Zhong, Zhao Jing-Jing, Liu Liang, Zhang Dong-Sheng, Wang Li-Ping, Hu Wen-Wei, Weng De-Sheng, Xu Xiang, Li Yi-Zhuo, Tang Yan, Zhang Wei-Hong, Li Jie-Yao, Zheng Xiao, Wang Qi-Jing, Li Yong-Qiang, Xiang Tong, Zhou Li, Yang Shuang-Ning, Wu Chen, Huang Rong-Xing, He Jia, Du Wei-Jiao, Chen Lu-Jun, Wu Yue-Na, Xu Bin, Shen Qiong, Zhang Yi, Jiang Jing-Ting, Ren Xiu-Bao, Xia Jian-Chuan
